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Background. The blunted immune response upon stimu-
lation in chronic renal failure (CRF) is often coupled to a
baseline inflammatory status which has been related to athero-
genesis. Uremic biologic fluids and several specific uremic re-
tention solutes alter cell-mediated immune responses, as well
as the interaction of calcitriol with the immune system.
Methods. The present study evaluated the influence of dif-
ferent guanidino compounds on DNA synthesis, chemilumines-
cence production, and CD14 expression of undifferentiated and
calcitriol-differentiated HL-60 cells. In a second setup, these
guanidino compounds were evaluated for their specific effect
on normal human leukocyte oxidative burst activity and tumor
necrosis factor-a (TNF-a) expression.
Results. First, several guanidino compounds elicited proin-
flammatory effects on leukocytes. Methylguanidine and guani-
dine stimulated the proliferation of undifferentiated HL-60
cells and the antiproliferative effect of calcitriol (P < 0.05)
was neutralized in the presence of methylguanidine (P <
0.05) and guanidinosuccinic acid (P < 0.05). The phorbol-
myristate-acetate (PMA)-stimulated chemiluminescence pro-
duction of the calcitriol differentiated HL-60 cells was enhanced
in the presence of guanidine (P < 0.05). Methylguanidine
and guanidinoacetic acid enhanced the lipopolysaccharide
(LPS)-stimulated intracellular production of TNF-a by normal
human monocytes (P < 0.05). Second, several guanidino com-
pounds inhibited the function of leukocytes if they were acti-
vated. The PMA-stimulated chemiluminescence production of
the calcitriol differentiated HL-60 cells was inhibited by the
presence of methylguanidine (P < 0.05), guanidinoacetic acid
(P < 0.05) and guanidinosuccinic acid (P < 0.05). After incu-
bation of whole blood in the presence of methylguanidine, the
Esherichia coli stimulated oxidative burst activity of the gran-
ulocyte population was significantly inhibited (P < 0.05). In
addition, guanidinosuccinic acid had an inhibitory effect on the
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LPS-stimulated intracellular production of TNF-a by human
monocytes (P < 0.01).
Conclusion. Guanidino compounds exert proinflammatory
as well as anti-inflammatory effects on monocyte/macrophage
function. This could contribute to the altered prevalence of car-
diovascular disease and propensity to infection in patients with
CRF.
Chronic renal failure (CRF) is characterized by func-
tional anomalies of the immune system [1], resulting in
an increased incidence of infection and a higher risk for
malignancy [2]. In end-stage renal disease (ESRD), the
blunted immune response upon stimulation is often as-
sociated with an activated baseline inflammatory status
which has been related to atherogenesis [3]. There is
now extensive evidence that atheromatosis is more fre-
quent and more severe in uremia [4–6]. It has been shown
that uremic biologic fluids alter cell-mediated immune
responses in vitro [7–9]. The influence of several spe-
cific uremic retention solutes such as p-cresol, purines,
several peptides (granulocyte inhibitory protein I and II,
ubiquitin-like peptide), advanced oxidation protein prod-
ucts, and advanced glycation end products (AGEs) on
biologic functions of immune-competent cells has been
demonstrated, both in a stimulatory and an inhibitory
way [8, 10–15].
In a previous study by our group, the effect of uremic ul-
trafiltrate (UUF) and fractions of the UUF on leukocyte
function was evaluated. Fraction 1 of the UUF elicited an
effect that was comparable to that of UUF per se, by en-
hancing the calcitriol-inhibited HL-60 cell proliferation
and by inhibiting its calcitriol-induced differentiation [9].
Guanidino compounds were found to coelute within this
fraction 1 of the UUF [16]. For that reason, we thought
that as a next step it was worthwhile to evaluate the in-
dividual impact of guanidines on elements of immune
function.
It is known that plasma and tissue levels of guanidino
compounds such as guanidine, guanidinosuccinic acid,
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and creatinine, which is the precursor of methylguani-
dine, and methylguanidine itself are highly increased in
uremic biologic fluids and tissues [17–20] and that sev-
eral guanidino compounds modify key biologic functions
[21–23].
Studies on the effect of guanidino compounds
on leukocyte function are relatively scarce, however.
Hirayama et al [24] described that a mixture of guani-
dino compounds suppresses the production of superoxide
by normal isolated neutrophils. Furthermore, guanidino
compounds such as guanidinosuccinic acid, creatinine,
and guanidinopropionic acid, have been shown to in-
hibit HL-60 and K562 cell line proliferation [25]. Finally,
Autore et al [26] reported that methylguanidine down-
regulates the tumor necrosis factor-a (TNF-a) release by
activated macrophages, but other guanidino compounds
were not evaluated. All these studies evaluated the im-
pact of guanidino compounds on activated leukocytes,
pointing to changes in the context of the uremic suscep-
tibility to infection, but the impact on baseline leukocyte
function, potentially involved in atherogenesis, was not
evaluated.
The present study evaluates the effect of different
specific guanidino compounds on the function of the
monocyte/macrophage phenotype, both at baseline and
after activation. The monocyte-macrophage is a criti-
cal cell type in atherogenesis because the attachment of
the activated monocyte to the vascular endothelium is
an early event in the genesis of the fatty streak lesion.
Our work uses representative parameters such as DNA
synthesis by estimation of the incorporation of 5-bromo-
2′-deoxyuridine (BrdU) into the DNA, free radical
production by the evaluation of the chemiluminescence
response and the oxidative burst activity of leukocytes,
and the intracellular production of TNF-a. In this way,
the study evaluates changes, due to presence of guani-
dino compounds, with a possible role in atherogenesis, as
well as in susceptibility to infection.
METHODS
Studies on HL-60 cells
For the first screening, HL-60 cells were used, with
as advantages, unlimited availability of leukocytes with
the monocyte/macrophage phenotype after culture in the
presence of calcitriol [27] and the possibility to pursue
long contact times with lasting cell viability.
Cell line culture
HL-60 cells were obtained from the American Type
Culture Collection (Rockville, MD, USA) and were
maintained as a continuous culture in RPMI 1640
medium supplemented with 2 mmol/L L-glutamine, 20%
heat-inactivated fetal bovine serum (FBS) (Life Tech-
nologies, Merelbeke, Belgium) and 50 lg/mL gentamycin
in a humidified atmosphere of 5% CO2 in air at 37◦C.
Medium was refreshed every 3 to 4 days. Cell cultures
were free of mycoplasma.
Experimental media
In this in vitro setup, HL-60 cells were cultured,
for 7 days, in (1) medium alone, (2) medium contain-
ing specific guanidino compounds, (3) medium contain-
ing 10 nmol/L calcitriol to differentiate HL-60 toward
the monocyte/macrophage phenotype, and (4) a com-
bination of (2) and (3). The experimental media (1)
and (2) were included as controls. Cell viability at the
moment of evaluation exceeded 90% as assessed by
propidium iodide exclusion on flow cytometry. The guani-
dino compounds (Sigma Chemical Co., St. Louis, MO,
USA) methylguanidine, guanidine, creatinine, guanidi-
noacetic acid, and guanidinosuccinic acid were dissolved
in RPMI 1640, respectively, at 8.4 lg/mL, 2.1 lg/mL,
240 lg/mL, 3.3 lg/mL, and 40 lg/mL, after which the
solutions were filtered through a 0.22 lm filter unit
(Millipore, Bedford, MA, USA). The applied concentra-
tions are ten times higher than the concentration which
had been determined in preliminary experiments in ul-
trafiltrates from hemodialysis patients (De Deyn et al,
unpublished observations).
All guanidino compound solutions used in this study
were found to be endotoxin-free (<0.2 IU/mL) (En-
dosafe Endochrome-KTM) (Charleston, SC, USA).
Evaluation methods for HL-60 cells
BrdU incorporation. After 1 week of incubation, cell
proliferation was evaluated by the measurement of the
incorporation of BrdU into DNA. Anti-BrdU (Becton
Dickinson, San Jose, CA, USA) was used in flow cyto-
metric analysis to identify cells that synthesized DNA
during exposure to BrdU (Sigma Chemical Co.).
Cells were incubated for 30 minutes with BrdU
(10 lmol/L) in the CO2 incubator at 37◦C. Af-
ter two washings with 1% bovine serum albumin
(BSA)/phosphate-buffered saline (PBS), the pellet was
resuspended in 200 lL of PBS on ice and to fix the cells,
this suspension was then slowly added to 5 mL of 70%
ethanol (−20◦C) followed by a 30-minute incubation pe-
riod on ice. After centrifugation and aspiration of the su-
pernatant, 1 mL 2 N HCl/0.5% Triton X-100 was slowly
added to the pellet followed by a 30-minute incubation
period at room temperature to denature the DNA. Af-
ter centrifugation, 1 mL of 0.1 mol/L Na2B4O4·10 H2O,
pH 8.5, was added to the pellet to neutralize the acid, fol-
lowed by a second centrifugation step. Cell concentration
was adjusted with 0.5% Tween/1.0% BSA/PBS to achieve
106 cells/test. Cells were incubated with fluorescein isoth-
iocyanate (FITC)-conjugated Anti-BrdU for 30 minutes
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and washed once in 1 mL 0.5% Tween/1.0% BSA/PBS,
and finally resuspended in PBS containing 5 lg/mL pro-
pidium iodide before analysis by a FACScan (Becton
Dickinson).
Chemiluminescence production. Chemiluminescence
production by HL-60 cells was determined after 1 week of
incubation in the different culture media and after read-
justment of the cell count to 1 × 106 cells/mL in every
sample. We added 500 lL of luminol solution (56 lmol/L)
and 100 lL of a phorbol 12-myristate 13-acetate (PMA)
solution (1.5 lg/mL, final concentration) to 50 lL of cell
suspension. The test tube was immediately processed
into a luminescence analyzer (Lumicon, Hamilton,
Switzerland). The photon-counting value, which is indi-
cated arbitrarily in relative light units (RLU), was regis-
tered with a counting interval set at 30 seconds and a total
recycling time of 30 minutes. Chemiluminescence pro-
duction was expressed as integrated chemiluminescence
emission in counts/30 min, chemiluminescence peak in
counts/min and chemiluminescence slope. The integral
considers the area under the curve of the chemilumines-
cence production over a time period of 30 minutes and
is the most complete parameter, the peak value is more
a snapshot of the upper limit of chemiluminescence pro-
duction and the slope learns about the kinetics of the ini-
tiation of the chemiluminescence production. The three
parameters together give a correct and overall image of
the chemiluminescence production.
Analysis of membrane bound CD14 expression on HL-
60 cells. Expression of CD14, a receptor for lipopolysac-
charide (LPS) and differentiation marker, was assessed
by direct immunofluorescence after 3 days of culture.
Fifty microliters cell suspension was incubated with
SimultestTM LeucogateTM (Becton Dickinson) at 4◦C
in the dark. SimultestTM LeucogateTM contains FITC-
conjugated CD45 monoclonal antibodies (Anti-HLe-1)
and phycoerythrin-conjugated CD14 monoclonal anti-
bodies (LeuTM-M3). After washing procedures, the cells
were submitted to flow cytometric analysis (FACScan)
(Becton Dickinson). Fluorescence was standardized by
microbeads (CalibriteTM particles) (Becton Dickinson)
with amplification and voltage kept constant throughout
the procedures. Analysis was performed on 10,000 events
(detector threshold FSC-H:200, parameter FSC-H:1.00).
The cell population was gated according to forward and
right angled light scatter. Background binding was es-
timated by isotype-matched negative control antibodies
(SimultestTM Control) (Becton Dickinson).
Studies on leukocytes in whole blood
During a second analytical phase, the guanidino com-
pounds were tested in whole blood and with application
of the maximal concentration (Cmax) [methylguanidine
(Curemic 0.77 lg/mL; Cmax 1.82 lg/mL); guanidine (Curemic
0.17 lg/mL; Cmax 0.80 lg/mL); creatinine (Curemic 136.0
lg/mL; Cmax 240.0 lg/mL); guanidinoacetic acid (Curemic
0.38 lg/mL; Cmax 0.69 lg/mL); guanidinosuccinic acid
(Curemic 6.5 lg/mL; Cmax 47.0 lg/mL)] as reported in ure-
mic patients in the literature [28–30]. Guanidino com-
pounds were dissolved in a 0.9% sodium chloride solution
(Baxter, Lessines, Belgium). The Cmax was used to com-
pensate for the shorter exposure times in these in vitro
experiments in whole blood compared to the chronic ex-
posure in vivo. All guanidino compound solutions used in
this study were found to be endotoxin-free (<0.2 IU/mL)
(Endosafe Endochrome-KTM) (Charleston, SC, USA).
Sample collection
Heparinized whole blood (sodium heparin Vacu-
tainer tubes) (Becton Dickinson) was collected from
healthy volunteers. The protocol was approved by the
local Ethical Committee and an informed consent was
obtained from all healthy donors.
Evaluation methods for whole blood
Quantification of oxidative burst activity. After a
10-minute incubation of the heparinized whole blood
with saline, methylguanidine, guanidine, creatinine,
guanidinoacetic acid, and guanidinosuccinic acid, the
Bursttest (Phagoburst) (Orpegen Pharma, Heidelberg,
Germany) was applied for a quantitative determina-
tion of the leukocyte oxidative burst activity, accord-
ing to manufacturer’s guidelines. Ice-cooled heparinized
whole blood was incubated with unlabeled opsonized
Escherichia coli (E. coli) as a particulate stimulus and
without stimulus for negative background control. The
generation of reactive oxygen metabolites during the ox-
idative burst was monitored by the addition and the de-
termination of oxidation of the fluorogenic substrate di-
hydrorhodamine (DHR) 123. The reaction was stopped
by addition of lysing solution (Becton Dickinson), which
removes the erythrocytes and results in a fixation of the
leukocytes. After a washing step, DNA staining solution
was added to exclude aggregation artifacts of bacteria or
cells. The percentage of cells having produced reactive
oxygen radicals as well as their mean fluorescence inten-
sity (MFI) (enzymatic activity) were analyzed and the
different leukocyte populations were identified based on
their light scattering properties using a FACScan (Bec-
ton Dickinson).
Intracellular TNF-a production. After a 10-minute in-
cubation of the heparinized whole blood with saline alone
as a control or with saline containing methylguanidine,
guanidine, creatinine, guanidinoacetic acid, and guanidi-
nosuccinic acid at Cmax, the blood was stimulated with
1 lg/mL LPS (Sigma Chemical Co.), and without LPS
for negative background control for 2 hours in a hu-
midified atmosphere of 5% CO2 in air at 37◦C. After
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Table 1. Effect of guanidino compounds on DNA synthesis of HL-60
cells
Calcitriol +
% BrdU-positive Guanidino guanidino
cells Medium compounds Calcitriol compounds
Methylguanidine 30.9 ± 5.4 34.7 ± 12.5a 23.4 ± 5.0b 27.6 ± 1.8c
Guanidine 28.9 ± 9.3 40.8 ± 13.6a 20.6 ± 9.6b 20.6 ± 7.3
Creatinine 30.5 ± 5.5 29.6 ± 10.2 23.3 ± 4.6b 22.8 ± 2.3
Guanidinoacetic 25.4 ± 1.5 24.7 ± 1.9 20.7 ± 3.6b 22.1 ± 5.5
acid
Guanidinosuccinic 19.4 ± 1.9 19.5 ± 5.0 14.7 ± 3.2b 19.6 ± 2.5c
acid
BruU is 5-bromo-2′-deoxyuridine. Mean ± SD (N = 6).
aP < 0.05 versus medium; bP < 0.01 versus medium; cP < 0.05 versus calcitriol.
this incubation period, 10 lg/mL Brefeldin A (BFA)
(Sigma Chemical Co.) was added to inhibit intracellu-
lar transport and to retain the cytokines inside the cell;
subsequently the incubation was continued for another
2 hours, after which FACS lysing solution was added to
lyse the erythrocytes and to fix the external epitopes. Then
the cells were permeabilized using FACS permeabiliz-
ing solution, after which they were stained for intracel-
lular TNF-a (FastimmuneTM Anti-Hu-TNF-a) (Becton
Dickinson) and with mouse Ig controls for estimation of
the aspecific binding. Samples were analyzed using the
FACScan (Becton Dickinson).
Statistical analysis
Data are expressed as means ± SD. Statistical analysis
was performed using one-way repeated measures analy-
sis of variance (ANOVA) followed by a paired Wicoxon
signed rank test in case of significant ANOVA. A P value
of less than 0.05 was considered significant.
RESULTS
Effect of different guanidines on HL-60 cell function
BrdU incorporation (DNA synthesis). The addition
of methylguanidine and guanidine (Table 1) in the cul-
ture medium significantly enhanced the DNA synthesis
(a marker of cell proliferation) of HL-60 (P < 0.05 ver-
sus medium). The presence of creatinine, guanidinoacetic
acid, and guanidinosuccinic acid in the culture medium,
on the other hand, had no effect on HL-60 cell DNA
synthesis.
When HL-60 cells were cultured in the presence of
calcitriol to differentiate the cells toward the mono-
cyte/macrophage phenotype, the percentage of cells in-
corporating BrdU (synthesizing DNA) was significantly
decreased, confirming the known antiproliferative effect
of calcitriol (P < 0.01 versus medium). The presence
of methylguanidine and guanidinosuccinic acid in the
calcitriol containing culture medium significantly coun-
teracted this antiproliferative effect of calcitriol (P <
Table 2. Effect of guanidino compounds on the characteristics of the
luminol-amplified chemiluminescence production of
phorbol-myristate-acetate (PMA)-stimulated HL-60 cells
Calcitriol +
Guanidino guanidino
Medium compounds Calcitriol compounds
Methylguanidine
Integral 5.3 ± 2.2 10.0 ± 7.0a 82.3 ± 79.0a 48.4 ± 49.0a,b
Peak 5.1 ± 3.4 8.7 ± 3.5 43.1 ± 10.5a 25.17 ± 9.3a,b
Slope 0.4 ± 0.5 0.6 ± 0.5 5.2 ± 1.9a 1.6 ± 0.6a,b
Guanidine
Integral 11.7 ± 11.4 26.1 ± 19.0a 154.3 ± 72.2a 208.5 ± 89.4a
Peak 13.5 ± 10.5 13.3 ± 5.5 92.7 ± 35.9a 132.3 ± 81.9a
Slope 2.1 ± 2.8 1.5 ± 1.4 14.2 ± 11.2a 27.0 ± 25.9a
Creatinine
Integral 4.9 ± 2.4 10.0 ± 6.3a 28.4 ± 15.6a 22.8 ± 11.6a
Peak 3.9 ± 1.8 5.5 ± 3.0 15.9 ± 10.4a 18.7 ± 8.5a
Slope 0.2 ± 2.1 0.4 ± 0.4 1.7 ± 1.6a 1.8 ± 1.4a
Guanidinoacetic acid
Integral 5.3 ± 3.2 8.1 ± 2.6 65.9 ± 13.1a 55.3 ± 8.1a,b
Peak 5.2 ± 2.3 7.2 ± 5.7 29.2 ± 6.3a 23.0 ± 3.7a
Slope 0.6 ± 0.6 0.8 ± 0.7 5.1 ± 1.9a 3.6 ± 0.8a
Guanidinosuccinic acid
Integral 3.8 ± 2.5 4.9 ± 4.5 14.1 ± 5.3a 16.1 ± 7.9a
Peak 6.8 ± 2.3 6.8 ± 3.8 24.1 ± 2.8a 19.4 ± 0.8a,b
Slope 0.7 ± 0.3 1.0 ± 0.4 4.9 ± 0.8a 2.8 ± 0.8a,b
Integral, cpm/30min/103; peak, cmp 103; slope, 103. Means ± SD (N = 6).
aP < 0.05 versus medium; bP < 0.05 versus calcitriol.
0.05 versus calcitriol) and induced again more DNA syn-
thesis. No effect of creatinine, guanidine, and guanidi-
noacetic acid in the presence of calcitriol was observed
(Table 1).
Because cell proliferation can be considered as a cel-
lular change enabling a more pronounced inflammatory
response, these data point out that at least some of the
guanidino compounds might contribute to the enhanced
inflammatory status in uremia.
Chemiluminescence-production. The effect of guani-
dino compounds on PMA stimulated chemilumi-
nescence production of undifferentiated HL-60 was
evaluated as a control. Table 1 illustrates that the pres-
ence of methylguanidine, guanidine, and creatinine in
the culture medium was found to enhance this response
for the integral (P < 0.05 versus medium), but not for
the peak or slope. Addition of calcitriol to the cul-
ture medium induced cell differentiation toward the
monocyte/macrophage phenotype, resulting in an en-
hanced chemiluminescence production. In this condition,
the PMA stimulated chemiluminescence production was
significantly inhibited when cells were cultured in the
presence of methylguanidine (integral, peak, and slope
values), guanidinoacetic acid (only the integral value),
and guanidinosuccinic acid (peak and slope values)
(P < 0.05 versus calcitriol) (Table 2) (representative ex-
periments in Fig. 1). In contrast, guanidine enhanced the
PMA-stimulated chemiluminescence production in a sig-
nificant way for the slope and peak values. The presence
of creatinine in the calcitriol containing culture medium
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Fig. 1. Representative time curves of luminal-dependent chemiluminescence (CL) assay from phorbol-myristate-acetate (PMA)-stimulated HL-60
cells. The cells were cultured in medium, in medium supplemented with guanidino compounds [methylguanidine (MG), guanidine (G), creatinine
(CTN), guanidinoacetic acid (GAA), and guanidinosuccinic acid (GSA)] both in the absence and the presence of calcitriol (C). Calcitriol-treated
cells are to be considered as the equivalent of monocyte/macrophage cells. In parallel to the average results illustrated in Table 2, there is a marked
decrease in response of the calcitriol-treated cells in the presence of methylguanidine and a less marked inhibition in the presence of guanidino
acetic acid and guanidinosuccinic acid. Guanidine, in contrast, has a stimulatory effect. The impact of creatinine is neutral.
did not influence the PMA stimulated chemilumines-
cence production values in either way (Fig. 1) (Table 2).
Even if no significant changes were found for some
indices of chemiluminescence production, the same trend
was maintained as for the significant findings under the
same conditions.
These data suggest that activation of chemilumines-
cence production (by guanidine) might be related to
the progression of enhanced inflammatory response and
atherogenesis, while be suppression of chemilumines-
cence production (by methylguanidine, guanidinoacetic
acid, and guanidinosuccinic acid) might be related to the
susceptibility to infection of the uremic patient.
CD14 expression. The expression of CD14 on HL-
60 cells was induced by the presence of calcitriol in the
culture medium. The presence of guanidino compounds
in the culture medium, on the other hand, had no effect
on the calcitriol-induced expression of membrane-bound
CD14 (data not shown).
Effect of the guanidines on normal human leukocytes
in whole blood
Oxidative burst activity. Guanidino compounds did
not alter the baseline oxidative burst activity of leuko-
cytes. None of the tested guanidino compounds had an
effect on the E. coli–stimulated production of reactive
oxygen species by normal monocytes. The E. coli stimu-
lated production of reactive oxygen species by granulo-
cytes, on the other hand, was inhibited when whole blood
was incubated in the presence of methylguanidine, with a
mean fluorescence of 427.0 ± 140.1 versus 464.5 ± 142.1
(P < 0.05). Guanidinoacetic acid, guanidine, creatinine,
and guanidinosuccinic acid had no effect on the E. coli–
stimulated oxidative burst activity of granulocytes.
These data further point out the potential role of
methylguanidine in the enhanced susceptibility to infec-
tion of the uremic patient.
Intracellular TNF-a production by LPS-stimulated
monocytes. Baseline TNF-a production by monocytes
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Fig. 2. Evaluation of the lipopolysaccharide (LPS)-stimulated intra-
cellular tumor necrosis factor-a (TNF-a) production by monocytes af-
ter incubation of whole blood. The evaluation was performed n the
presence of methylguanidine (MG), guanidine (G), creatinine (CTN),
guanidinoacetic acid (GAA), and guanidinosuccinic acid (GSA) com-
pared to saline. ∗P < 0.05 versus saline (N = 8).
was negligible with a percentage of 2.26 ± 0.40 TNF-a–
positive cells. The presence of methylguanidine, guani-
dine, creatinine, guanidinoacetic acid, and guanidinosuc-
cinic acid did not influence baseline TNF-a production.
The LPS-stimulated intracellular production of TNF-a
by monocytes, on the other hand, was significantly en-
hanced when whole blood was incubated in the presence
of methylguanidine and guanidinoacetic acid (P < 0.05)
(Fig. 2). In contrast, incubation of whole blood in the pres-
ence of guanidinosuccinic acid had a slight but significant
inhibitory effect on the LPS-stimulated monocytic intra-
cellular production of TNF-a (P < 0.01) (Fig. 2). Incuba-
tion of whole blood in the presence of methylguanidine,
guanidine, creatinine, guanidinoacetic acid, and guanidi-
nosuccinic acid did not influence the percentage of TNF-
a–positive monocytes (data not shown). Incubation of
whole blood in the presence of guanidine and creatinine,
however, had no significant effect on the LPS-stimulated
monocytic intracellular production of TNF-a, although
there was a trend for increase. More production of TNF-
a for the majority of studied guanidino compounds points
to a proinflammatory and proatherogenic impact.
DISCUSSION
In this in vitro study, the effect of different guanidino
compounds on the function of leukocytes was evaluated.
In an initial experiment, using the HL-60 cell line, the
effect of methylguanidine, guanidine, creatinine, guani-
dinoacetic acid, and guanidinosuccinic acid on specific
parameters such as BrdU incorporation (DNA synthe-
sis), chemiluminescence response (free radical produc-
tion) and CD14 expression (differentiation marker and
receptor for LPS) was studied in the absence (as control)
and the presence of calcitriol (summarized in Table 3).
Calcitriol is known to differentiate HL-60 cells toward
the monocyte/macrophage phenotype. The second exper-
imental set up, using whole blood, tested the effect of
guanidino compounds on the oxidative burst activity and
intracellular TNF-a production of leukocytes in whole
blood (summarized in Table 4).
Some of the tested guanidino compounds were
found to elicit proinflammatory responses. Methylguani-
dine and guanidine enhanced the basal cell prolifera-
tion of undifferentiated HL-60 cells. The proliferation
of the calcitriol-differentiated HL-60 cells increased
when cultured in the presence of methylguanidine
and guanidinosuccinic acid. In addition, guanidine en-
hanced the PMA-stimulated chemiluminescence pro-
duction of calcitriol-differentiated HL-60 cells and the
LPS-stimulated TNF-a production by monocytes was in-
creased after incubation with methylguanidine and guani-
dinoacetic acid.
Conversely, under certain conditions, guanidino com-
pounds also elicited an anti-inflammatory response.
Methylguanidine and guanidinoacetic acid suppressed
the PMA-stimulated chemiluminescence production of
calcitriol-differentiated HL-60 cells. Methylguanidine
also suppressed the E. coli–stimulated oxidative burst
activity of granulocytes and guanidinosuccinic acid
decreased the LPS-stimulated TNF-a production by
monocytes.
These results illustrate, specifically for the guanidines,
the dual response of the immune system in uremia. This
dual response has been suggested by other studies as well.
On one hand, baseline immune function is considered
to be activated which might be related to atherogenesis
[5, 31]; on the other hand, stimulated immune function
is often suppressed [7], which may be related to the sus-
ceptibility for infection. According to our data, several
guanidines play a role in this process. It is of note that in-
fectious disease in its turn induces inflammation and that
specific infections such as Chlamydia pneumoniae have
been suggested to be related to atherogenesis both in the
normal [32] and the uremic population [33].
Because cell proliferation can be considered as a
cellular change reflecting an inflammatory response,
our data on the enhanced cell proliferation of HL-
60 cells cultured in the presence of methylguanidine
and guanidine and on the neutralization of the an-
tiproliferative effect of calcitriol by methylguanidne and
guanidinosuccinic acid could point in the direction of the
involvement of guanidino compounds in the enhanced
inflammatory status in uremia. In contrast, Nathan et al
[25] reported that creatinine, guanidinopropionic acid,
and guanidinosuccinic acid inhibit the growth of HL-60
cells and of the erythroleukemia cell line K562. It is of
note, however, that these authors applied concentrations
up to 200 times higher than those used in the present
study; in addition, proliferation was determined by count-
ing the colony formation on tissue culture dishes, which
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Table 3. Effect of different guanidines on HL-60 cell function
DNA Chemiluminescence
synthesis in production in
DNA the presence Chemiluminescence the presence CD14
synthesis of calcitriol production of calcitriol expression
Methylguanidine P < 0.05 ↑ P < 0.05 ↑ P < 0.05 ↑ P < 0.05 ↓ NS
Guanidine P < 0.05 ↑ NS P < 0.05 ↑ P < 0.05 ↑ NS
Creatinine NS NS P < 0.05 ↑ NS NS
Guanidinoacetic acid NS NS NS P < 0.05 ↓ NS
Guanidinosuccinic acid NS P < 0.05 ↑ NS P < 0.05 ↓ NS
Table 4. Effect of guanidines on normal human leukocytes
Oxidative burst Oxidative burst Lipopolysaccharide-stimulated
E. coli- E. coli- intracellular tumor necrosis
stimulated stimulated monocytes factor-a (TNF-a)
granulocytes monocytes production by monocytes
Methylguanidine P < 0.05 ↓ NS P < 0.05 ↑
Guanidine NS NS NS
Creatinine NS NS NS
Guanidinoacetic acid NS NS P < 0.05 ↑
Guanidinosuccinic acid NS NS P < 0.05 ↓
is a less accurate method compared to the flow cytomet-
ric method used in this study. Our data also demonstrate
the pro-inflammatory effect of guanidine on the PMA-
stimulated chemiluminescence production of calcitriol
differentiated HL-60 cells and on the LPS-stimulated in-
tracellular production of TNF-a by normal monocytes.
It is known that the monocyte respiratory burst leads
to activation of nuclear factor-kappaB (NF-jB) [34], a
transcription factor directly involved in the activation
of genes responsible for inflammation [35] and present
in atherosclerotic lesions [36]. In addition, TNF-a elic-
its diverse biologic responses involved in atherosclero-
sis, such as secretion of proinflammatory cytokines and
expression of adhesion molecules [37]. It serves as an
endogenous mediator of inflammatory, immune, and host
defense functions [38] and is mainly synthesized by cells
of the monocyte/macrophage phenotype.
Serum TNF-a concentration has been found to be el-
evated in patients with CRF [39, 40]. The reason for this
evolution has yet not been elucidated but is probably
multifactorial. Retention of guanidines could be a pos-
sible trigger for enhanced TNF-a production by mono-
cyte/macrophage. In contrast, in a study by Autore et
al [26], methylguanidine inhibited the TNF-a release by
activated macrophages, but again these results were ob-
tained at concentrations 100 times higher than the ones
used in the present study.
Simultaneously, anti-inflammatory responses in the
presence of some of the guanidino compounds were
observed, as demonstrated by the inhibition of the
calcitriol-induced and PMA-stimulated chemilumines-
cence response by HL-60 cells cultured in the presence
of guanidinoacetic acid and methylguanidine and by the
inhibitory effect of guanidinosuccinic acid on the LPS-
stimulated intracellular TNF-a production by normal
monocytes. An inhibition of the zymosan-stimulated su-
peroxide production in the presence of guanidinosuccinic
acid, guanidinopropionic acid, and guanidinobutyric acid
and by a guanidino compound mix (guanidinosuccinic
acid, guanidinopropionic acid, guanidinobutyric acid,
methylguanidine, and guanidinoacetic acid) had already
been demonstrated for the neutrophilic cell population
[24]. The data demonstrating the anti-inflammatory effect
of guanidino compounds could implicate the impaired
function of monocyte/macrophages in host defense and
the enhanced propensity to infection in uremia.
The question might be raised why different guanidines
have an opposite impact on different aspects of leukocyte
functional response. A possible explanation is that these
functions are not interrelated, and that guanidino com-
pounds, in part due to the heterogeneity of their chemical
structure, might exert distinct effects on distinct mech-
anisms of leukocyte response. The discrepancies might
in part be attributable as well to methodologic factors.
When the HL-60 cell line was studied using chemilu-
minescence, we evaluated cells uniquely of the mono-
cyte/macrophage phenotype, while the oxidative burst
activity was studied using whole blood which allows cell
to cell (erythrocyte-thrombocyte-monocyte-lymphocyte-
granulocyte) interaction during incubation. In the latter
case, the activity of the different cell types is made only af-
terwards by flow cytometric analysis. Hence, cells of the
monocytic phenotype have been submitted to different
stimuli if they were isolated (as in the HL-60 model) or
submitted to the cross-talk with other cells (as in whole
blood).
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It is of note that the present data match the data from
our previous studies where an increase in the prolifer-
ation of calcitriol-differentiated HL-60 cells and inhibi-
tion of the chemiluminescence production was observed
in the presence of UUF and fraction 1 of this UUF [9].
Guanidines were identified to elute within this fraction 1
[16].
Finally, since virtually every cell type composing the
vascular wall has been shown to produce reactive oxy-
gen species, it would be interesting, in the context of the
pathogenesis of atherosclerotic lesions, to study the effect
of guanidino compounds on the reactive oxygen species
production by endothelial and/or vascular smooth mus-
cle cells [41]. The question should be raised in how far
the present data regarding reactive oxygen species pro-
duction by leukocytes can be extrapolated to cells of the
vessel wall.
CONCLUSION
Guanidino compounds were shown to exert proinflam-
matory as well as anti-inflammatory effects on mono-
cyte/macrophage function. These effects could contribute
to the altered prevalence of cardiovascular disease and
the propensity to infection in patients with ESRD.
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